Dr Reddy's Laboratories Ltd (RDY) Stock AnalysisRDYDr Reddy's Laboratories Ltd

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dr. Reddy's Laboratories Ltd is a good buy right now due to its current price of $13.07, which is below the analyst price target of $14.80, indicating a potential upside of 13.2%. Additionally, the stock has shown a positive momentum with a 5-day change of +4.73% and a strong RSI of 75.546, suggesting it is gaining traction. However, a risk to consider is the last earnings report, which showed an EPS of 0.06, significantly missing the estimate of 0.17, leading to a price drop of -9.39%.

1 analysts cover RDY: 0 rate it Buy, 0 Hold and 1 Sell.